Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8442) 8442
Book Review (1539) 1539
Publication (501) 501
Newspaper Article (67) 67
Magazine Article (50) 50
Book Chapter (37) 37
Conference Proceeding (36) 36
Book / eBook (17) 17
Newsletter (4) 4
Web Resource (3) 3
Dissertation (1) 1
Government Document (1) 1
Paper (1) 1
Report (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7449) 7449
humans (5657) 5657
animals (3027) 3027
chelating agents - therapeutic use (2946) 2946
male (2832) 2832
female (2305) 2305
iron chelating agents - therapeutic use (1772) 1772
adult (1334) 1334
chelating agents - pharmacology (1197) 1197
rats (1178) 1178
mice (1105) 1105
pharmacology & pharmacy (1099) 1099
chelating agents (1057) 1057
middle aged (906) 906
iron (883) 883
biochemistry & molecular biology (823) 823
iron - metabolism (813) 813
child (753) 753
chelating agents - chemistry (748) 748
hematology (729) 729
adolescent (700) 700
deferoxamine - therapeutic use (698) 698
treatment outcome (695) 695
oxidative stress (663) 663
iron chelating agents - pharmacology (661) 661
chelation therapy (658) 658
toxicology (604) 604
abridged index medicus (598) 598
iron overload - drug therapy (578) 578
deferoxamine (572) 572
aged (534) 534
edetic acid - therapeutic use (495) 495
chelation (490) 490
time factors (490) 490
therapy (488) 488
analysis (477) 477
pyridones - therapeutic use (449) 449
child, preschool (443) 443
toxicity (441) 441
iron overload (427) 427
deferiprone (413) 413
oncology (405) 405
health aspects (378) 378
copper (371) 371
iron overload - etiology (371) 371
chelating agents - administration & dosage (370) 370
ferritins - blood (369) 369
urology & nephrology (362) 362
desferrioxamine (361) 361
benzoates - therapeutic use (359) 359
care and treatment (359) 359
liver - metabolism (357) 357
triazoles - therapeutic use (357) 357
dose-response relationship, drug (356) 356
thalassemia (354) 354
antioxidants (349) 349
cancer (341) 341
iron chelating agents - administration & dosage (336) 336
neurosciences (336) 336
beta-thalassemia (334) 334
lead poisoning - drug therapy (333) 333
transfusion reaction (333) 333
tissue distribution (324) 324
penicillamine - therapeutic use (321) 321
in-vitro (320) 320
medicine, general & internal (319) 319
deferasirox (318) 318
chemistry, medicinal (317) 317
blood transfusion (308) 308
proteins (307) 307
calcium (306) 306
research (305) 305
administration, oral (304) 304
beta-thalassemia - drug therapy (304) 304
rats, wistar (303) 303
ligands (295) 295
iron chelating agents - adverse effects (294) 294
disease models, animal (291) 291
cell line, tumor (290) 290
young adult (289) 289
chelating agents - adverse effects (283) 283
article (278) 278
drug therapy, combination (274) 274
antioxidants - pharmacology (271) 271
zinc (267) 267
overload (265) 265
metabolism (264) 264
disease (259) 259
iron chelating agents - chemistry (259) 259
rats, sprague-dawley (259) 259
liver (258) 258
magnetic resonance imaging (258) 258
cells (256) 256
endocrinology & metabolism (256) 256
calcium - metabolism (253) 253
apoptosis (250) 250
copper - metabolism (250) 250
deferoxamine - pharmacology (248) 248
dentistry (243) 243
cells, cultured (242) 242
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7970) 7970
French (157) 157
Russian (103) 103
German (97) 97
Italian (56) 56
Japanese (55) 55
Spanish (50) 50
Polish (30) 30
Chinese (24) 24
Czech (12) 12
Dutch (10) 10
Portuguese (8) 8
Romanian (8) 8
Danish (5) 5
Hebrew (5) 5
Hungarian (4) 4
Bulgarian (2) 2
Croatian (2) 2
Lithuanian (2) 2
Norwegian (2) 2
Slovak (2) 2
Turkish (2) 2
Finnish (1) 1
Korean (1) 1
Serbian (1) 1
Slovenian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
by Devos, David and Moreau, Caroline and Devedjian, Jean Christophe and Kluza, Jérome and Petrault, Maud and Laloux, Charlotte and Jonneaux, Aurélie and Ryckewaert, Gilles and Garçon, Guillaume and Rouaix, Nathalie and Duhamel, Alain and Jissendi, Patrice and Dujardin, Kathy and Auger, Florent and Ravasi, Laura and Hopes, Lucie and Grolez, Guillaume and Firdaus, Wance and Sablonnière, Bernard and Strubi-Vuillaume, Isabelle and Zahr, Noel and Destée, Alain and Corvol, Jean-Christophe and Pöltl, Dominik and Leist, Marcel and Rose, Christian and Defebvre, Luc and Marchetti, Philippe and Cabantchik, Z. Ioav and Bordet, Régis
Antioxidants & Redox Signaling, ISSN 1523-0864, 07/2014, Volume 21, Issue 2, pp. 195 - 210
Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with... 
Original Research Communication | NEURODEGENERATIVE DISORDERS | OXIDATIVE STRESS | DELAYED-START TRIAL | INTRACELLULAR LABILE IRON | BIOCHEMISTRY & MOLECULAR BIOLOGY | ENDOCRINOLOGY & METABOLISM | CLINICAL-IMPLICATIONS | DOUBLE-BLIND | DOPAMINERGIC-NEURONS | THALASSEMIA MAJOR | SUBSTANTIA-NIGRA | FRIEDREICH ATAXIA | Cell Line | Iron Chelating Agents - therapeutic use | Double-Blind Method | Humans | Mice, Inbred C57BL | Motor Activity - drug effects | Male | Combined Modality Therapy | Parkinson Disease - drug therapy | Iron - metabolism | Pyridones - administration & dosage | Pilot Projects | Animals | Iron Chelating Agents - administration & dosage | Mice | Parkinson Disease - metabolism | Pyridones - therapeutic use | Oxidative Stress - drug effects | Pyridones - pharmacology | Disease Models, Animal | Care and treatment | Iron | Parkinson's disease | Research | Chemical properties | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
by Ayton, Scott and Lei, Peng and Duce, James A and Wong, Bruce X. W and Sedjahtera, Amelia and Adlard, Paul A and Bush, Ashley I and Finkelstein, David I
Annals of Neurology, ISSN 0364-5134, 04/2013, Volume 73, Issue 4, pp. 554 - 559
Ceruloplasmin is an iron‐export ferroxidase that is abundant in plasma and also expressed in glia. We found a ∼80% loss of ceruloplasmin ferroxidase activity... 
LIPID-PEROXIDATION | GENE | NIGRAL IRON DEPOSITION | FERROXIDASE ACTIVITY | NEURONS | EXPORT | SERUM | COPPER | SUPEROXIDE-DISMUTASE | SUBSTANTIA-NIGRA | NEUROSCIENCES | CLINICAL NEUROLOGY | Ceruloplasmin - deficiency | Iron Chelating Agents - therapeutic use | Parkinson Disease - pathology | Humans | Male | Parkinson Disease - drug therapy | Substantia Nigra - metabolism | Ceruloplasmin - therapeutic use | Case-Control Studies | Mice, Knockout | Animals | Ceruloplasmin - metabolism | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Female | Aged | Mice | Parkinson Disease - metabolism | Pyridones - therapeutic use | Disease Models, Animal | Dopamine Agents | Parkinson Disease - etiology | Parkinsons disease | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials
by Palmer, Suetonia C., PhD and Gardner, Sharon, MA and Tonelli, Marcello, MD and Mavridis, Dimitris, PhD and Johnson, David W., PhD and Craig, Jonathan C., PhD and French, Richard, MBChB and Ruospo, Marinella, MScMed and Strippoli, Giovanni F.M., PhD
American Journal of Kidney Diseases, ISSN 0272-6386, 2016, Volume 68, Issue 5, pp. 691 - 702
Background Guidelines preferentially recommend noncalcium phosphate binders in adults with chronic kidney disease (CKD). We compare and rank phosphate-binder... 
Nephrology | calcium | lanthanum | Phosphate-binding agents | mortality | meta-analysis | phosphate binder | sevelamer | iron | chronic kidney disease (CKD) | LANTHANUM CARBONATE | AORTIC CALCIFICATION | OPEN-LABEL | CALCIUM-CARBONATE | FERRIC CITRATE | CORONARY-ARTERY CALCIFICATION | DIALYSIS PATIENTS | HEMODIALYSIS-PATIENTS | UROLOGY & NEPHROLOGY | CHRONIC KIDNEY-DISEASE | Phosphates | Sevelamer - therapeutic use | Humans | Adult | Network Meta-Analysis | Chelating Agents - therapeutic use | Lanthanum - therapeutic use | Randomized Controlled Trials as Topic | Renal Insufficiency, Chronic - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease
by Sang, Zhipei and Li, Yan and Qiang, Xiaoming and Xiao, Ganyuan and Liu, Qiang and Tan, Zhenghuai and Deng, Yong
Bioorganic and Medicinal Chemistry, ISSN 0968-0896, 02/2015, Volume 23, Issue 4, pp. 668 - 680
To discover multifunctional agents for the treatment of Alzheimer's disease (AD), a series of scutellarein carbamate derivatives were designed and synthesized... 
Neuroprotective effects | Scutellarein carbamate derivatives | Metal-chelating agents | Alzheimer's disease | Cholinesterase inhibitors | Antioxidant activity | OXIDATIVE STRESS | DESIGN | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | CARBAMATE DERIVATIVES | CHEMISTRY, ORGANIC | CHOLINESTERASE-INHIBITORS | ACETYLCHOLINESTERASE | METALS | HYDROGEN-PEROXIDE | AGENTS | BRAIN | Neuroprotective Agents - therapeutic use | Cholinesterase Inhibitors - pharmacokinetics | Antioxidants - chemistry | Apigenin - therapeutic use | Humans | Cholinesterase Inhibitors - chemistry | Carbamates - pharmacokinetics | Carbamates - chemistry | Apigenin - chemistry | Chelating Agents - pharmacokinetics | Neuroprotective Agents - pharmacokinetics | Butyrylcholinesterase - metabolism | Glucuronates - therapeutic use | Glucuronates - chemistry | Chelating Agents - therapeutic use | Cell Line | Neuroprotective Agents - chemistry | Chelating Agents - chemistry | Alzheimer Disease - drug therapy | Rats | Apigenin - pharmacokinetics | Cognition - drug effects | Blood-Brain Barrier - metabolism | Glucuronates - pharmacokinetics | Antioxidants - therapeutic use | Animals | Alzheimer Disease - metabolism | Mice | Molecular Docking Simulation | Antioxidants - pharmacokinetics | Carbamates - therapeutic use | Cholinesterase Inhibitors - therapeutic use | Acetylcholinesterase - metabolism | Antioxidants | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Effects of phosphate binders in moderate CKD
by Block, Geoffrey A and Wheeler, David C and Persky, Martha S and Kestenbaum, Bryan and Ketteler, Markus and Spiegel, David M and Allison, Matthew A and Asplin, John and Smits, Gerard and Hoofnagle, Andrew N and Kooienga, Laura and Thadhani, Ravi and Mannstadt, Michael and Wolf, Myles and Chertow, Glenn M
Journal of the American Society of Nephrology, ISSN 1046-6673, 08/2012, Volume 23, Issue 8, pp. 1407 - 1415
Some propose using phosphate binders in the CKD population given the association between higher levels of phosphorus and mortality, but their safety and... 
MORTALITY | VITAMIN-D | CORONARY-ARTERY CALCIUM | SERUM PHOSPHATE | GROWTH-FACTOR 23 | CARDIOVASCULAR-DISEASE | UROLOGY & NEPHROLOGY | CHRONIC KIDNEY-DISEASE | FGF23 | PHOSPHORUS BINDERS | PROGRESSION | Humans | Middle Aged | Male | Polyamines - therapeutic use | Parathyroid Hormone - blood | Renal Insufficiency, Chronic - complications | Bone Density - drug effects | Pilot Projects | Calcium Compounds - therapeutic use | Fibroblast Growth Factors - blood | Hyperphosphatemia - etiology | Hyperphosphatemia - prevention & control | Phosphates - urine | Vascular Calcification - chemically induced | Aged, 80 and over | Phosphates - blood | Female | Acetates - therapeutic use | Aged | Sevelamer | Chelating Agents - therapeutic use | Lanthanum - therapeutic use | Index Medicus | Clinical Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Therapeutic macromolecular iron chelators
by Bulbake, Upendra and Singh, Alka and Domb, Abraham J and Domb, Abraham J and Khan, Wahid and Khan, Wahid
Current Medicinal Chemistry, ISSN 0929-8673, 2019, Volume 26, Issue 2, pp. 323 - 334
Iron is a key element for every single living process. On a fundamental level, targeting iron is a valuable approach for the treatment of disorders caused by... 
deferiprone | iron chelators | Polymeric iron chelators, iron chelators, deferoxamine, deferiprone, deferasirox | Polymeric iron chelators | deferoxamine | deferasirox | HYDROXAMIC ACID | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | UNDERMINE PATIENT SAFETY | DEFERASIROX LOOPHOLES | THALASSEMIA MAJOR | IRON(III)-CHELATING PROPERTIES | PHARMACOKINETICS | RECORD NUMBER | PHARMACOLOGY & PHARMACY | INHIBITORS | BETA-THALASSEMIA | Polymers - therapeutic use | Iron Chelating Agents - therapeutic use | Animals | Iron Overload - drug therapy | Humans | Cell Line, Tumor | Antimalarials - therapeutic use | Antineoplastic Agents - therapeutic use | Malaria - drug therapy | Neoplasms - drug therapy | Vector-borne diseases | Therapy | Malaria | Neurodegenerative diseases | Toxicity | Macromolecules | Disorders | Iron | Pharmacology | Foaming agents | Chemical compounds | Hemosiderosis | Molecular weight | Low molecular weights | Chelation | Chelating agents | Half life | Cancer
Journal Article
Details down arrow
7. Full Text Multifunctional gold nanostar-based nanocomposite: Synthesis and application for noninvasive MR-SERS imaging-guided photothermal ablation
by Gao, Yongping and Li, Yongsheng and Chen, Jianzhuang and Zhu, Shaojia and Liu, Xiaohang and Zhou, Liangping and Shi, Ping and Niu, Dechao and Gu, Jinlou and Shi, Jianlin
Biomaterials, ISSN 0142-9612, 2015, Volume 60, pp. 31 - 41
Abstract We report here the design and facile synthesis of multifunctional gold nanostars based nanocomposites (MGSNs) through direct organosilica coating onto... 
Advanced Basic Science | Dentistry | Photothermal therapy | Gold | Nanocomposite | MRI | SERS | HIGH-PERFORMANCE | MATERIALS SCIENCE, BIOMATERIALS | NANOPROBES | PHOTODYNAMIC THERAPY | CONTRAST AGENTS | ENGINEERING, BIOMEDICAL | NANORODS | LIVING MICE | CANCER-DETECTION | NANOSHELLS | IN-VIVO | RAMAN NANOPARTICLE | Gold - chemistry | Nanocomposites - therapeutic use | Nanocomposites - chemistry | Humans | Chelating Agents - chemistry | Magnetic Resonance Imaging - methods | Polyethylene Glycols - chemistry | Spectrum Analysis, Raman - methods | Polyethylene Glycols - therapeutic use | Neoplasms - therapy | Phototherapy - methods | Animals | Heterocyclic Compounds - chemistry | Organosilicon Compounds - chemistry | Organosilicon Compounds - therapeutic use | Cell Line, Tumor | Gold - therapeutic use | Organometallic Compounds - therapeutic use | Nanocomposites - ultrastructure | Organometallic Compounds - chemistry | Mice, Inbred BALB C | Heterocyclic Compounds - therapeutic use | Neoplasms - pathology | Chelating Agents - therapeutic use | Magnetic resonance imaging | Anisotropy | Chelates | Index Medicus | Surgical implants | Biomedical materials | Synthesis | Imaging | Nanostructure | Ablation | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A 1-Year Randomized Trial of Calcium Acetate Versus Sevelamer on Progression of Coronary Artery Calcification in Hemodialysis Patients With Comparable Lipid Control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) Study
by Qunibi, Wajeh, MD and Moustafa, Moustafa, MD and Muenz, Larry R., PhD and He, David Y., MS and Kessler, Paul D., MD and Diaz-Buxo, Jose A., MD and Budoff, Mathew, MD and CARE-2 Investigators
American Journal of Kidney Diseases, ISSN 0272-6386, 2008, Volume 51, Issue 6, pp. 952 - 965
Background Previous clinical trials showed that progression of coronary artery calcification (CAC) may be slower in hemodialysis patients treated with... 
Nephrology | dialysis | electron-beam computed tomography (EBCT) | secondary hyperparathyroidism | hyperphosphatemia | statins | vascular calcification | Cardiovascular disease | cholesterol | dyslipidemia | atorvastatin | low-density lipoprotein | YOUNG-ADULTS | MORTALITY | cardiovascular disease | LOWERING THERAPY | ATHEROSCLEROSIS | BEAM COMPUTED-TOMOGRAPHY | CLINICAL CARDIOLOGY | CARDIOVASCULAR-DISEASE | MAINTENANCE HEMODIALYSIS | UROLOGY & NEPHROLOGY | CHRONIC KIDNEY-DISEASE | ASSOCIATION | Prospective Studies | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Coronary Artery Disease - prevention & control | Male | Polyamines - therapeutic use | Disease Progression | Atorvastatin Calcium | Anticholesteremic Agents - therapeutic use | Calcium Compounds - therapeutic use | Time Factors | Female | Acetates - therapeutic use | Calcinosis - prevention & control | Sevelamer | Pyrroles - therapeutic use | Chelating Agents - therapeutic use | Renal Dialysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia
by Cappellini, MD and Cohen, A and Piga, A and Bejaoui, M and Perrone, S and Agaoglu, L and Aydinok, Y and Kattamis, A and Kilinc, Y and Porter, J and Capra, M and Galanello, R and Fattoum, S and Drelichman, G and Magnano, C and Verissimo, M and Athanassiou-Metaxa, M and Giardina, P and Kourakli-Symeonidis, A and Janka-Schaub, G and Coates, T and Vermylen, C and Olivieri, N and Thuret, I and Opitz, H and Ressayre-Djaffer, C and Marks, P and Alberti, D
BLOOD, ISSN 0006-4971, 05/2006, Volume 107, Issue 9, pp. 3455 - 3462
Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic iron overload from blood transfusions. A comparative phase 3... 
OVERLOAD | TRIAL | CELLS | THERAPY | DEFEROXAMINE | STORES | SAFETY | TREATED PATIENTS | HEMATOLOGY | DEFERIPRONE | Benzoates - adverse effects | Triazoles - administration & dosage | Triazoles - adverse effects | Benzoates - therapeutic use | Humans | Middle Aged | Child, Preschool | Deferoxamine - therapeutic use | Male | Adult | Female | Iron Chelating Agents - administration & dosage | Safety | Child | Triazoles - therapeutic use | Iron Chelating Agents - therapeutic use | Drug Administration Schedule | Administration, Oral | Liver - metabolism | Iron - metabolism | Benzoates - administration & dosage | Iron Chelating Agents - adverse effects | beta-Thalassemia - drug therapy | Adolescent | beta-Thalassemia - metabolism | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer
by Gamelin, Laurence and Boisdron-Celle, Michele and Delva, Remy and Guérin-Meyer, Véronique and Ifrah, Norbert and Morel, Alain and Gamelin, Erick
Clinical Cancer Research, ISSN 1078-0432, 07/2004, Volume 10, Issue 12 I, pp. 4055 - 4061
Purpose: Oxaliplatin is active in colorectal cancer. Sensory neurotoxicity is its dose-limiting toxicity. It may come from an effect on neuronal voltage-gated... 
TRIAL | CHANNELS | NEUROPATHY | ONCOLOGY | FLUOROURACIL | CHEMOTHERAPY | Paresthesia - prevention & control | Calcium Gluconate - therapeutic use | Humans | Middle Aged | Male | Treatment Outcome | Magnesium Sulfate - therapeutic use | Antineoplastic Agents - toxicity | Magnesium - therapeutic use | Fluorouracil - therapeutic use | Organoplatinum Compounds - toxicity | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Calcium - therapeutic use | Female | Leucovorin - therapeutic use | Aged | Retrospective Studies | Chelating Agents - therapeutic use | Laryngismus - prevention & control | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease
by Perez, Lissette R and Franz, Katherine J
Dalton Transactions, ISSN 1477-9226, 2010, Volume 39, Issue 9, pp. 2177 - 2187
Neurodegenerative diseases like Alzheimer's and Parkinson's disease are associated with elevated levels of iron, copper, and zinc and consequentially high... 
AMYLOID-BETA PEPTIDE | CLEAVAGE AGENTS | OXIDATIVE STRESS | ALZHEIMERS-DISEASE | HYDROXYL RADICAL SCAVENGER | HYDROGEN-PEROXIDE | IRON-CHELATORS | THERAPEUTIC APPROACH | MONOAMINE-OXIDASE INHIBITION | PARKINSONS-DISEASE | CHEMISTRY, INORGANIC & NUCLEAR | Metals - therapeutic use | Metals - chemistry | Neurodegenerative Diseases - drug therapy | Chelating Agents - therapeutic use | Humans | Chelating Agents - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients
by Suki, W.N and Zabaneh, R and Cangiano, J.L and Reed, J and Fischer, D and Garrett, L and Ling, B.N and Chasan-Taber, S and Dillon, M.A and Blair, A.T and Burke, S.K
Kidney International, ISSN 0085-2538, 11/2007, Volume 72, Issue 9, pp. 1130 - 1137
Elevated serum phosphorus and calcium are associated with arterial calcification and mortality in dialysis patients. Unlike calcium-based binders, sevelamer... 
hemodialysis | mortality | sevelamer | calcium | phosphate-binders | phosphorus | Phosphate-binders | Phosphorus | Sevelamer | Calcium | Hemodialysis | Mortality | SURVIVAL | VITAMIN-D | CARDIOVASCULAR CALCIFICATION | CORONARY | RISK | DIALYSIS | MAINTENANCE HEMODIALYSIS | UROLOGY & NEPHROLOGY | MINERAL METABOLISM | ASSOCIATION | STAGE RENAL-DISEASE | Acetates - adverse effects | Age Factors | Polyamines - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Polyamines - therapeutic use | Calcium - blood | Calcium Compounds - adverse effects | Calcium Compounds - therapeutic use | Renal Dialysis - mortality | Cardiovascular Diseases - mortality | Adult | Female | Acetates - therapeutic use | Kidney Diseases - complications | Chelating Agents - therapeutic use | Chelating Agents - adverse effects | Cardiovascular Diseases - etiology | Calcium Carbonate - therapeutic use | Treatment Outcome | Calcium Carbonate - adverse effects | Phosphorus - blood | Kidney Diseases - therapy | Aged | Chronic Disease | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text A prospective study of the factors affecting outcomes of nonsurgical root canal treatment: part 1: periapical health
by Ng, Y.‐L and Mann, V and Gulabivala, K
International Endodontic Journal, ISSN 0143-2885, 07/2011, Volume 44, Issue 7, pp. 583 - 609
P>Aim To investigate the probability of and factors influencing periapical status of teeth following primary (1 degrees RCTx) or secondary (2 degrees RCTx)... 
periapical healing | success | outcome | root canal treatment | Root canal treatment | Outcome | Periapical healing | Success | LONG-TERM | ORTHOGRADE RETREATMENT | PRIMARY ENDODONTIC INFECTIONS | CHLORHEXIDINE GLUCONATE | SODIUM-HYPOCHLORITE | MINERAL TRIOXIDE AGGREGATE | QUALITY GUIDELINES | BACTERIOLOGIC EVALUATION | DENTISTRY, ORAL SURGERY & MEDICINE | APICAL PERIODONTITIS | OF-THE-LITERATURE | Prognosis | Prospective Studies | Follow-Up Studies | Gutta-Percha - therapeutic use | Humans | Periapical Diseases - diagnostic imaging | Male | Dental Pulp Cavity - pathology | Contraindications | Periapical Tissue - pathology | Root Canal Therapy - methods | Toothache - prevention & control | Adult | Dental Pulp Cavity - injuries | Female | Root Canal Preparation - instrumentation | Chlorhexidine | Chelating Agents - therapeutic use | Periapical Diseases - therapy | Root Canal Irrigants - therapeutic use | Treatment Outcome | Root Canal Preparation - methods | Root Canal Filling Materials - therapeutic use | Radiography | Retreatment | Post and Core Technique | Wound Healing - physiology | Dental Fistula - pathology | Zinc Oxide-Eugenol Cement - therapeutic use | Edetic Acid - therapeutic use | Sodium Hypochlorite - therapeutic use | Cohort Studies | Periapical Tissue - diagnostic imaging | Tooth Apex - pathology | Analysis | Root canal therapy | Dentistry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights